If one is to believe Jim Tobin, chairman and CEO of Boston Scientific (Natick, Massachusetts), his company lucked into becoming the second company in the U.S. to have a drug-eluting stent (DES) on the market, and by his account, “king of [drug-eluting] stents,” with more than 70% of the market share in the DES space.